Inhibition of Adenovirus Replication by CRISPR-Cas9-mediated Targeting of the Viral E1A Gene

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2023 Mar 23

PMID 36950281

Authors

Zrinka Didara

Florian Reithofer

Karina Zottl

Alexander Jurets

Izabella Kiss

Angela Witte

Reinhard Klein

Affiliations

Soon will be listed here.

Abstract

DNA-targeting CRISPR-Cas systems are able to cleave dsDNA in mammalian cells. Accordingly, they have been employed to target the genomes of dsDNA viruses, mostly when present in cells in a non-replicative state with low copy numbers. However, the sheer amount of viral DNA produced within a very short time by certain lytically replicating viruses potentially brings the capacities of CRISPR-Cas systems to their limits. The accessibility of viral DNA replication sites, short time of accessibility of the DNA before encapsidation, or its complexation with shielding proteins are further potential hurdles. Adenoviruses are fast-replicating dsDNA viruses for which no approved antiviral therapy currently exists. We evaluated the potency of CRISPR-Cas9 in inhibiting the replication of human adenovirus 5 by targeting its master regulator with a set of guide RNAs and observed a decrease in infectious virus particles by up to three orders of magnitude. Target DNA cleavage also negatively impacted the amount of viral DNA accumulated during the infection cycle. This outcome was mainly caused by specific deletions, inversions, and duplications occurring between target sites, which abolished most E1A functions in most cases. Additionally, we compared two strategies for multiplex gRNA expression and obtained comparable results.

Citing Articles

Advanced gene therapy system for the treatment of solid tumour: A review.

Ma Y, Liao J, Cheng H, Yang Q, Yang H Mater Today Bio. 2024; 27:101138.

PMID: 39027677 PMC: 11255123. DOI: 10.1016/j.mtbio.2024.101138.

References

Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T . Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002; 12(9):735-9. DOI: 10.1016/s0960-9822(02)00809-6. View

Macias S, Cordiner R, Caceres J . Cellular functions of the microprocessor. Biochem Soc Trans. 2013; 41(4):838-43. DOI: 10.1042/BST20130011. View

Lion T . Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014; 27(3):441-62. PMC: 4135893. DOI: 10.1128/CMR.00116-13. View

Ramakrishna S, Cho S, Kim S, Song M, Gopalappa R, Kim J . Surrogate reporter-based enrichment of cells containing RNA-guided Cas9 nuclease-induced mutations. Nat Commun. 2014; 5:3378. DOI: 10.1038/ncomms4378. View

Clement K, Rees H, Canver M, Gehrke J, Farouni R, Hsu J . CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol. 2019; 37(3):224-226. PMC: 6533916. DOI: 10.1038/s41587-019-0032-3. View

Kojaoghlanian T, Flomenberg P, Horwitz M . The impact of adenovirus infection on the immunocompromised host. Rev Med Virol. 2003; 13(3):155-71. DOI: 10.1002/rmv.386. View

Kalesnykas G, Kokki E, Alasaarela L, Lesch H, Tuulos T, Kinnunen K . Comparative Study of Adeno-associated Virus, Adenovirus, Bacu lovirus and Lentivirus Vectors for Gene Therapy of the Eyes. Curr Gene Ther. 2017; 17(3):235-247. DOI: 10.2174/1566523217666171003170348. View

Wollebo H, Bellizzi A, Kaminski R, Hu W, White M, Khalili K . CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection. PLoS One. 2015; 10(9):e0136046. PMC: 4567079. DOI: 10.1371/journal.pone.0136046. View

Callahan B, Wong J, Heiner C, Oh S, Theriot C, Gulati A . High-throughput amplicon sequencing of the full-length 16S rRNA gene with single-nucleotide resolution. Nucleic Acids Res. 2019; 47(18):e103. PMC: 6765137. DOI: 10.1093/nar/gkz569. View

10.

Goncalves M, de Vries A . Adenovirus: from foe to friend. Rev Med Virol. 2006; 16(3):167-86. DOI: 10.1002/rmv.494. View

11.

Kleinstiver B, Pattanayak V, Prew M, Tsai S, Nguyen N, Zheng Z . High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016; 529(7587):490-5. PMC: 4851738. DOI: 10.1038/nature16526. View

12.

Pelka P, Ablack J, Shuen M, Yousef A, Rasti M, Grand R . Identification of a second independent binding site for the pCAF acetyltransferase in adenovirus E1A. Virology. 2009; 391(1):90-8. DOI: 10.1016/j.virol.2009.05.024. View

13.

Robinson C, Singh G, Lee J, Dehghan S, Rajaiya J, Liu E . Molecular evolution of human adenoviruses. Sci Rep. 2013; 3:1812. PMC: 3648800. DOI: 10.1038/srep01812. View

14.

Hartline C, Gustin K, Wan W, Ciesla S, Beadle J, Hostetler K . Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis. 2005; 191(3):396-9. DOI: 10.1086/426831. View

15.

Paolino K, Sande J, Perez E, Loechelt B, Jantausch B, Painter W . Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. J Clin Virol. 2010; 50(2):167-70. DOI: 10.1016/j.jcv.2010.10.016. View

16.

Wang D, Tai P, Gao G . Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019; 18(5):358-378. PMC: 6927556. DOI: 10.1038/s41573-019-0012-9. View

17.

Berk A . Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene. 2005; 24(52):7673-85. DOI: 10.1038/sj.onc.1209040. View

18.

Marshall K, Cohen M, Fonseca G, Todorovic B, King C, Yousef A . Identification and characterization of multiple conserved nuclear localization signals within adenovirus E1A. Virology. 2014; 454-455:206-14. DOI: 10.1016/j.virol.2014.02.020. View

19.

Doench J, Fusi N, Sullender M, Hegde M, Vaimberg E, Donovan K . Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016; 34(2):184-191. PMC: 4744125. DOI: 10.1038/nbt.3437. View

20.

Cundy K . Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999; 36(2):127-43. DOI: 10.2165/00003088-199936020-00004. View